Clinical Trials
21 trialsNCT06903858 2026-05-22
PICC-3
Sun Yat-sen University
Phase 2 Recruiting
NCT03607890 2026-03-16
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04104893 2026-02-27
CHOMP
VA Office of Research and Development
Phase 2 Active not recruiting
NCT03767348 2026-02-13
IGNYTE
Replimune, Inc.
Phase 2 Active not recruiting
NCT07403877 2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2 Not yet recruiting
NCT07266025 2026-01-27
CATALIS
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07369986 2026-01-27
IMMUNE-SAVE
Women's Hospital School Of Medicine Zhejiang University
Phase 2 Not yet recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT07259473 2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT03926338 2025-11-20
PICC
Sun Yat-sen University
Phase 2 Recruiting
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT05118724 2025-06-15
ANTONIO
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT06646445 2025-06-13
PREMICES
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT02983578 2025-05-06
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06278857 2024-12-03
SATELLITE
Queensland Centre for Gynaecological Cancer
Phase 2 Recruiting
NCT05913570 2023-06-22
MSI-H/dMMR
Henan Cancer Hospital
Phase 2 Unknown
NCT05371197 2022-05-12
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04001101 2021-11-30
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
Phase 2 Withdrawn
NCT04439214 2021-04-06
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03150706 2020-04-03
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Asan Medical Center
Phase 2 Unknown